NCT06536725 Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis
| NCT ID | NCT06536725 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University Second Hospital |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 35 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35 participants in total. It began in 2024-06-01 with a primary completion date of 2025-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.
Eligibility Criteria
Inclusion Criteria: 1. Patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically; 2. Age ≥ 18 years old; 3. ECOG score ≤ 2 points or ECOG score 3-4 points due to tumor progression; 4. Normal liver and kidney function, serum transaminase ALT\<66 U/L, AST\<36 U/L, total bilirubin\<22 umol/L, creatinine\<106 umol/L, urea nitrogen\<6.1 mmol/L; Normal bone marrow function: neutrophil count ≥ 1800/mm3 and platelet count ≥ 100000/mm3; 5. Can obtain surgical or biopsy samples; 6. Patients voluntarily join this study and sign an informed consent form. Exclusion Criteria: 1. Patients with severe heart, liver, kidney, and peripheral nervous system diseases, as well as autoimmune diseases such as hyperthyroidism and hypothyroidism; Systemic lupus erythematosus, etc; 2. Patients who are unable to obtain tissue samples; 3. Subjects with active pulmonary tuberculosis (TB); 4. Subjects who are preparing for or have previously undergone tissue/organ transplantation; 5. Exclusion criteria are not listed, but the researchers believe that patients who are not suitable to participate in this clinical study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06536725 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06536725 currently recruiting?
Yes, NCT06536725 is actively recruiting participants. Contact the research team at peterrock2000@126.com for enrollment information.
Where is the NCT06536725 trial being conducted?
This trial is being conducted at Tianjin, China, Tianjin, China.
Who is sponsoring the NCT06536725 clinical trial?
NCT06536725 is sponsored by Tianjin Medical University Second Hospital. The trial plans to enroll 35 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.